Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

Fig. 3

Compared mean survivals (calculated using Weibull model) irrespective of histology (a), in squamous histology (b), and non-squamous histology (c); orange bars denote immunotherapies, blue bars targeted therapies, and green bars chemotherapies

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us